Breaking News, Collaborations & Alliances

GenScript, NuclixBio Partner on Circular RNA Therapeutics

Establishes first large-scale production process for circular RNA therapeutics from preclinical to clinical stages with GMP production.

GenScript ProBio, a global CDMO, and NuclixBio, a company that develops treatments based on circular RNA, have entered into a strategic agreement to develop the first circular RNA-based anticancer drug in South Korea. With this strategic partnership, both companies will establish the first large-scale production process for circular RNA therapeutics in South Korea from preclinical to clinical stages (with GMP production). This also serves as a cornerstone for NuclixBio’s of its circular...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters